Acute Coronary Syndrome Drug Development Pipeline Analysis Report 2018 - ResearchAndMarkets.com

July 30, 2018

DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “2018 Acute Coronary Syndrome Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Acute Coronary Syndrome Market” report has been added to ResearchAndMarkets.com’s offering.

Worldwide, an estimated 2 to 3 million people are hospitalized due to ACS annually. The acute coronary syndrome is a common complication of coronary heart disease. ACS refers to a broad range of diseases including Unstable angina, Non-ST segment elevation MI, ST-segment elevation MI. A sudden decrease in blood flow into the heart is observed, eventually resulting in thrombotic occlusion of a coronary artery. A sustained block of blood flow to the heart causes the death of the muscle tissue.

To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Acute Coronary Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials. Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Acute Coronary Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided.

In addition to complete details of each product, the report provides key trends in Acute Coronary Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Companies Mentioned

Actelion Pharmaceuticals Ltd. advanceCor GmbH Allergan plc Ascendia Pharmaceuticals LLC Bayer AG Cardiome Pharma Corp. Cerenis Therapeutics Holding SA CSL Limited DalCor Pharmaceuticals Canada Inc. PT. Dexa Medica HitGen LTD LipimetiX Development Inc MedImmune LLC Pfizer Inc. Resverlogix Corporation Verseon Corporation

Key Topics Covered:

1 Table of Contents

2 Acute Coronary Syndrome Pipeline Analysis

3 Acute Coronary Syndrome- Company Wise Pipeline Analysis

4 Acute Coronary Syndrome R&D Pipeline Snapshots

5 Recent Developments in Acute Coronary Syndrome Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/x39b9v/acute_coronary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005301/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Cardiovascular Drugs ,Clinical Trials



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 06:20 AM/DISC: 07/30/2018 06:21 AM


Update hourly